Balanced Solutions Voluntarily Recalls Sterile Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Balanced Solutions Voluntarily Recalls Sterile Products


Balanced Solutions Compounding Pharmacy, a division of Axium Healthcare Pharmacy, of Lake Mary, Florida, has announced a voluntarily recall of all lots of its sterile non-expired drug products due to a lack of sterility assurance and concerns with product quality controls, according to FDA. This is the third compounding pharmacy to issue a recall this month. NuVision Pharmacy and ApothéCure announced recalls due to sterility concerns on April 15.

FDA states that during an inspection of Balanced Solutions’ facility investigators observed poor practices and conditions, which may have exposed the company’s sterile products to microbial contamination. Further analysis confirmed FDA concerns. FDA identified gram-negative bacteria, a type of contaminant, in a sample chromium chloride injection from Balanced Solutions. According to FDA, Gram-negative bacteria can cause disease and many types of infection, but the Sphingobacterium thalpophilum bacteria found in the solution does not usually cause infection in humans.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here